1:08 PM
Apr 16, 2018
 |  BC Extra  |  Clinical News

Blueprint reports early data for RET inhibitor

Blueprint Medicines Corp. (NASDAQ:BPMC) reported data from the Phase I ARROW trial of BLU-667 to treat ret proto-oncogene (RET)-altered solid tumors. BLU-667 is a RET inhibitor.

Among 14 evaluable patients with RET-altered non-small cell lung cancer (NSCLC), once-daily BLU-667 led to an overall response rate (ORR) of 50%, including five confirmed partial responses (PRs) and two unconfirmed PRs.


Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >